News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Takeda Pharmaceuticals North America, Inc.'s Actos Has Same Heart Risks as GlaxoSmithKline’s Avandia, Researchers Find
August 25, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Takeda Pharmaceutical Co.’s diabetes drug Actos causes as many heart problems as Avandia, the GlaxoSmithKline Plc pill that had a decline in sales after being linked to higher heart-disease rates, a study found.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
Takeda
GSK
MORE ON THIS TOPIC
Earnings
Merck drops early-stage TROP ADC, keeps deal doors open as Keytruda clock ticks
April 30, 2026
·
5 min read
·
Gabrielle Masson
Huntington’s disease
UniQure eyes UK approval for embattled Huntington’s gene therapy after FDA quarrel
April 30, 2026
·
2 min read
·
Heather McKenzie
Schizophrenia
Patient death prompts FDA pause on Newron’s Phase 3 schizophrenia study
April 30, 2026
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints
April 30, 2026
·
2 min read
·
Tristan Manalac
